TAS6417

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerNSCLC, Stage IB-IIIAAdvanced or Metastatic NSCLC

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Yervoy

Bristol-Myers Squibb

Preclinical

312

TAS6417

Taiho Oncology, Inc.

Phase 3

13

Gemzar

GGynecologic Oncology Group

Preclinical

724

PORTRAZZA

Eli Lilly

Preclinical

85

Lenvima

Eisai

Preclinical

66

Imjudo

AstraZeneca

Preclinical

57

Vizimpro

Pfizer

Preclinical

48

Gilotrif

Boehringer Ingelheim

Preclinical

129

Ofev

Boehringer Ingelheim

Preclinical

710

Immunotherapy

Bristol-Myers Squibb

Preclinical

12Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Active, not recruiting·Taiho Oncology, Inc.·Phase 3·NCT05973773·285 enrolled

NSCLC, Stage IB-IIIA1 trial

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients With Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Active, not recruiting·Taiho Oncology, Inc.·Phase 3·NCT07128199·360 enrolled

Advanced or Metastatic NSCLC1 trial

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Recruiting·Taiho Oncology, Inc.·Phase 2·NCT05967689·220 enrolled

Details

Drug Info

Related News